| __timestamp | Celldex Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 179279000 |
| Thursday, January 1, 2015 | 4011000 | 186359000 |
| Friday, January 1, 2016 | 102026000 | 171785000 |
| Sunday, January 1, 2017 | 96171000 | 208136000 |
| Monday, January 1, 2018 | 66449000 | 198405000 |
| Tuesday, January 1, 2019 | 42672000 | 224169000 |
| Wednesday, January 1, 2020 | 42534000 | 245044000 |
| Friday, January 1, 2021 | 3068000 | 252314000 |
| Saturday, January 1, 2022 | 1400000 | 268225000 |
| Sunday, January 1, 2023 | 3008000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Taro Pharmaceutical Industries Ltd. and Celldex Therapeutics, Inc. present a fascinating study in contrasts over the past decade. From 2014 to 2023, Taro consistently maintained a higher cost of revenue, peaking at approximately 324% of Celldex's highest recorded cost in 2014. This reflects Taro's expansive operations and market reach. Meanwhile, Celldex's cost of revenue saw a dramatic decline, plummeting by over 97% from its 2014 peak to 2022, indicating strategic shifts or operational efficiencies. Notably, Taro's costs surged by 70% from 2014 to 2023, underscoring its growth trajectory. The absence of data for Celldex in 2024 suggests potential restructuring or data reporting changes. These trends offer a window into the strategic priorities and market positioning of these pharmaceutical players.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Amgen Inc. and Taro Pharmaceutical Industries Ltd.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Evotec SE
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.